Clinical trial · Observational
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
A Prospective, Observational, Long-term Follow-up Study for Subjects Who Previously Received Zamtocabtagene Autoleucel in a North American Miltenyi Biomedicine-Sponsored Clinical Study
NCT06116110CI-TRIAL-00120591recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is an observational long-term follow-up (LTFU) study for subjects who previously received zamtocabtagene autoleucel, known as MB-CART2019.1.
Conditions
Conditions (6)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Central Nervous System Lymphoma | Central Nervous System Lymphoma | ONTOLOGY_EXACT | 0.90 |
| High Grade B-cell Lymphoma | High Grade B-Cell Lymphoma | CURATED_BROADER | 0.80 |
| Non Hodgkin Lymphoma | Non-Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.90 |
| Primary Mediastinal B-cell Lymphoma (PMBCL) | Primary Mediastinal Large B-Cell Lymphoma | ALIAS | 0.85 |
| Refractory Diffuse Large B Cell Lymphoma (DLBCL) | Diffuse Large B-Cell Lymphoma | CURATED_BROADER | 0.78 |
| Relapsed Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Long-term Follow-Up | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Long-term Follow-Up
- description
- No intervention
- interventionNames
- Other: Long-term Follow-Up
Primary outcomes (5)
- measure
- Number of subjects with new or recurrence of pre-existing malignancy
- timeFrame
- Up to 15 years
- measure
- Number of subjects with new incidence or exacerbation of a pre-existing neurological disorder
- timeFrame
- Up to 15 years
- measure
- Number of subjects with new incidence or exacerbation of pre-existing rheumatologic or other autoimmune disorders
- timeFrame
- Up to 15 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Received zamtocabtagene autoleucel in a North American Miltenyi Biomedicine-sponsored clinical study and have not withdrawn consent to be followed or been deemed lost to follow-up. * Provided written informed consent to participate in this study. Exclusion Criteria: * None
References
Publications (0)
Data not yet available
No reference posted for this study.